胃癌治療薬の世界市場2016-2020

◆英語タイトル:Global Gastric Cancer Drugs Market 2016-2020
◆商品コード:IRTNTR7982
◆発行会社(調査会社):Technavio
◆発行日:2015年12月16日
◆ページ数:99
◆レポート言語:英語
◆レポート形式:pdf
◆納品方法:Eメール
◆調査対象地域:世界
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、胃癌治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、胃癌治療薬の世界市場規模及び予測、投与経路(ROA)別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

Technavio’s market research analyst predicts the global gastric cancer drugs market to grow rapidly at a CAGR of approximately 8% during the forecast period. The presence of huge unmet needs in the market is expected to result in this market’s healthy growth during the forecast period. The presence of this high-unmet medical need will lead to an increased R&D of safe and effective drugs, which in turn will spur market growth during the estimated period.

The recent increase in the prevalence of gastric cancer due to lifestyle changes is expected to drive market growth. The sedentary lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity are envisaged to result in the increased incidence of gastric cancer.

Geographical segmentation and analysis of the gastric cancer drugs market
• Americas
• APAC
• Europe

In this market study, analysts have estimated the APAC region to account for the highest market share during the forecast period. Much of this region’s growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive market share of nearly 48% during the forecast period.

The global gastric cancer drugs market is growing rapidly owing to the high proportion of individuals with gastric cancer and the presence of a strong drug pipeline. To gain traction in this market, the vendors are manufacturing and marketing gastric cancer drugs that exhibit a high safety and efficacy profile, this helps the vendors to gain a competitive edge over their peers.

The top vendors in the market are –
• Hoffmann-La Roche
• Eli-lilly
• Sanofi
• Otsuka Holdings

Other prominent vendors in the market include Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, and Celgene.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction

PART 05: Disease overview
• Understanding the disease
• Pathophysiology
• Causes
• Signs and symptoms
• Diagnosis
• Staging
• Japanese staging system
• Treatment
• Epidemiology
• Economic burden

PART 06: Pipeline portfolio
• Information on pipeline candidates

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by molecule type
• Small molecules
• Biologics

PART 09: Market segmentation by route of administration
• Oral
• Parenteral

PART 10: Market segmentation by lines of chemotherapy
• First-line chemotherapy
• Second-line chemotherapy

PART 11: Geographical segmentation
• Global gastric cancer drugs market by geographical segmentation 2015-2020
• Gastric cancer drugs market in APAC
• Gastric cancer drugs market in Japan
• Gastric cancer drugs market in China
• Gastric cancer drugs market in Americas
• Gastric cancer drugs market in EMEA

PART 12: Market drivers
• Promising drug pipeline
• Unmet medical needs
• Increase in patient population
• Patient assistance programs

PART 13: Impact of drivers

PART 14: Market challenges
• High cost of drugs
• Adverse side effects
• Shortage of drugs
• Delayed diagnosis

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Rise in public awareness
• Use of off-label drugs
• Intense competition among vendors

PART 17: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• Eli Lilly

PART 18: Key vendor analysis
• Eli Lilly
• F. Hoffmann-La Roche
• Otsuka Holdings
• Sanofi
• Other prominent vendors

PART 19: Appendix
• List of abbreviation

PART 20: Explore Technavio

Exhibit 01: Product offerings 9
Exhibit 02: Types of gastric cancer
Exhibit 03: Frequency of different types of gastric cancers
Exhibit 04: Causes of gastric cancer
Exhibit 05: Signs and symptoms of gastric cancer
Exhibit 06: Diagnostic tests for gastric cancer
Exhibit 07: Staging of gastric cancer
Exhibit 08: Treatment options for gastric cancer
Exhibit 09: First-line therapy for metastatic or locally advanced gastric cancer
Exhibit 10: Second-line therapy for gastric cancer
Exhibit 11: Surgeries for gastric cancer
Exhibit 12: Types of radiation therapy for gastric cancer
Exhibit 13: Estimated number of new cancers (all ages) males and females in Americas, EMEA, and APAC: 2015 and 2020
Exhibit 14: Estimated number of new cancers (age <65 and >=65) males and females in Americas, EMEA, and APAC: 2015
Exhibit 15: Estimated number of mortality cases (all ages) males and females in Americas, EMEA, and APAC: 2015
Exhibit 16: Estimated number of mortality cases (age <65 and >=65) males and females in Americas, EMEA, and APAC: 2015
Exhibit 17: Pipeline molecules for gastric cancer
Exhibit 18: Gastric cancer clinical trials by development phase
Exhibit 19: Gastric cancer clinical trials by trial status
Exhibit 20: Global gastric cancer drugs market 2015-2020 ($ millions)
Exhibit 21: Five forces analysis
Exhibit 22: Global gastric cancer drugs market segmented by molecule type
Exhibit 23: Global gastric cancer drugs market segmented by route of administration
Exhibit 24: Dose and administration schedule of Teysuno (S-1) plus cisplatin
Exhibit 25: Lines of therapy for the treatment of advanced gastric cancer
Exhibit 26: Estimated annual cost per patient for chemotherapy regimen in EU ($ millions)
Exhibit 27: Global gastric cancer drugs market by geographical segmentation 2015
Exhibit 28: Global gastric cancer drugs market region wise 2015-2020 ($ millions)
Exhibit 29: Gastric cancer drugs market in APAC 2015-2020 ($ millions)
Exhibit 30: Gastric cancer drugs market in Japan 2015-2020 ($ millions)
Exhibit 31: Gastric cancer drugs market in China 2015-2020 ($ millions)
Exhibit 32: Gastric cancer drugs market in Japan and China 2015-2020 ($ millions)
Exhibit 33: Gastric cancer drugs market in Americas 2015-2020 ($ millions)
Exhibit 34: Gastric cancer drugs market in EMEA 2015-2020 ($ millions)
Exhibit 35: Key drivers for global gastric cancer drugs market
Exhibit 36: Number of patients treated with Herceptin via Patient Assistance Program in China
Exhibit 37: Impact of drivers
Exhibit 38: Challenges of global gastric cancer drugs market
Exhibit 39: Average cost comparison of Herceptin
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Trends of global gastric cancer drugs market
Exhibit 42: Timeline of Cyramza in US, EU, and Japan
Exhibit 43: Eli Lilly: Key takeaways
Exhibit 44: Timeline of Herceptin in US, EU, and Japan
Exhibit 45: F. Hoffmann-La Roche: Global YoY growth and revenue of Herceptin 2011-2014 ($ millions)
Exhibit 46: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in US 2013-2014 ($ millions)
Exhibit 47: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in EU 2013-2014 ($ millions)
Exhibit 48: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in Japan 2013-2014 ($ millions)
Exhibit 49: F. Hoffmann-La Roche: Key takeaways
Exhibit 50: Timeline of Tegafur in Japan, EU, and Asia
Exhibit 51: Otsuka Holdings: Key takeaways
Exhibit 52: Timeline of Taxotere in US, EU, and Japan
Exhibit 53: Sanofi: Global YoY growth and revenue of Taxotere 2011-2014 ($ millions)
Exhibit 54: Sanofi: YoY growth and revenue of Taxotere in US 2011-2014 ($ millions)
Exhibit 55: Sanofi: YoY growth and revenue of Taxotere in EU 2011-2014 ($ millions)
Exhibit 56: Sanofi: Key takeaways
Exhibit 57: Eli Lilly: Business segmentation by revenue 2014
Exhibit 58: Eli Lily: Business/Product segmentation by revenue 2012 and 2013 ($ millions)
Exhibit 59: Eli Lily: Geographical segmentation by revenue 2014
Exhibit 60: F. Hoffmann-La Roche: Business segmentation by revenue 2014
Exhibit 61: F. Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 62: F. Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 63: Otsuka Holdings: Business segmentation 2014 by revenue
Exhibit 64: Otsuka Holdings: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 65: Otsuka Holdings: Geographical segmentation by revenue 2014
Exhibit 66: Sanofi: Business segmentation by revenue 2014
Exhibit 67: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 68: Sanofi: Geographical segmentation by revenue 2014



【掲載企業】

Hoffmann-La Roche, Eli-lilly, Sanofi, Otsuka Holdings, Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, Celgene.

【レポートのキーワード】

胃癌、胃癌治療薬、医薬品、製薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[胃癌治療薬の世界市場2016-2020]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年07月28日現在 197,496 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆